Exact Mass: 293.1176
Exact Mass Matches: 293.1176
Found 500 metabolites which its exact mass value is equals to given mass value 293.1176,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
typhon
CONFIDENCE standard compound; INTERNAL_ID 553; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9257; ORIGINAL_PRECURSOR_SCAN_NO 9255 CONFIDENCE standard compound; INTERNAL_ID 553; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9197; ORIGINAL_PRECURSOR_SCAN_NO 9195 CONFIDENCE standard compound; INTERNAL_ID 553; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9205; ORIGINAL_PRECURSOR_SCAN_NO 9203 CONFIDENCE standard compound; INTERNAL_ID 553; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9250; ORIGINAL_PRECURSOR_SCAN_NO 9246 CONFIDENCE standard compound; INTERNAL_ID 553; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4784; ORIGINAL_PRECURSOR_SCAN_NO 4780 CONFIDENCE standard compound; INTERNAL_ID 553; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4767; ORIGINAL_PRECURSOR_SCAN_NO 4764 CONFIDENCE standard compound; INTERNAL_ID 553; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4773; ORIGINAL_PRECURSOR_SCAN_NO 4771 ORIGINAL_ACQUISITION_NO 4761; CONFIDENCE standard compound; INTERNAL_ID 553; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_PRECURSOR_SCAN_NO 4756 CONFIDENCE standard compound; INTERNAL_ID 553; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9251; ORIGINAL_PRECURSOR_SCAN_NO 9247 CONFIDENCE standard compound; INTERNAL_ID 553; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9148; ORIGINAL_PRECURSOR_SCAN_NO 9147 CONFIDENCE standard compound; INTERNAL_ID 553; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4768; ORIGINAL_PRECURSOR_SCAN_NO 4764 CONFIDENCE standard compound; INTERNAL_ID 553; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4761; ORIGINAL_PRECURSOR_SCAN_NO 4756 CONFIDENCE standard compound; INTERNAL_ID 553; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4740; ORIGINAL_PRECURSOR_SCAN_NO 4739 KEIO_ID T112; [MS2] KO009258 KEIO_ID T112; [MS3] KO009259 KEIO_ID T112; [MS3] KO009260 D016573 - Agrochemicals D010575 - Pesticides KEIO_ID T112
Oxaprozin
Oxaprozin is only found in individuals that have used or taken this drug. It is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.Anti-inflammatory effects of Oxaprozin are believed to be due to inhibition of cylooxygenase in platelets which leads to the blockage of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Oxaprozin is a non-selective NSAID, with a cell assay system showing lower COX-2 selectivity implying higher COX-1 selectivity. M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AE - Propionic acid derivatives D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics C471 - Enzyme Inhibitor > C1323 - Cyclooxygenase Inhibitor D000893 - Anti-Inflammatory Agents D004791 - Enzyme Inhibitors Oxaprozin is an orally active and potent COX inhibitor, with IC50 values of 2.2 μM for human platelet COX-1 and and 36 μM for IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB. Oxaprozin induces cell apoptosis. Oxaprozin shows anti-inflammatory activity. Oxaprozin-mediated inhibition of the Akt/IKK/NF-κB pathway contributes to its anti-inflammatory properties[1][2].
Ondansetron
Ondansetron is a well tolerated drug with few side effects. Headache, constipation, and dizziness are the most commonly reported side effects associated with its use. There have been no significant drug interactions reported with this drugs use. It is broken down by the hepatic cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system; Ondansetron is a serotonin 5-HT3 receptor antagonist used mainly to treat nausea and vomiting following chemotherapy. Its effects are thought to be on both peripheral and central nerves. One part is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata, the other is a blockage of serotonin receptors in the chemoreceptor trigger zone. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors; A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties; Ondansetron (INN) is a serotonin 5-HT3 receptor antagonist used mainly to treat nausea and vomiting following chemotherapy. Its effects are thought to be on both peripheral and central nerves. One part is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata, the other is a blockage of serotonin receptors in the chemoreceptor trigger zone. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors. [HMDB] Ondansetron is a well tolerated drug with few side effects. Headache, constipation, and dizziness are the most commonly reported side effects associated with its use. There have been no significant drug interactions reported with this drugs use. It is broken down by the hepatic cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system; Ondansetron is a serotonin 5-HT3 receptor antagonist used mainly to treat nausea and vomiting following chemotherapy. Its effects are thought to be on both peripheral and central nerves. One part is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata, the other is a blockage of serotonin receptors in the chemoreceptor trigger zone. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors; A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties; Ondansetron (INN) is a serotonin 5-HT3 receptor antagonist used mainly to treat nausea and vomiting following chemotherapy. Its effects are thought to be on both peripheral and central nerves. One part is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata, the other is a blockage of serotonin receptors in the chemoreceptor trigger zone. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors. A - Alimentary tract and metabolism > A04 - Antiemetics and antinauseants > A04A - Antiemetics and antinauseants > A04AA - Serotonin (5ht3) antagonists C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist > C94726 - 5-HT3 Receptor Antagonist D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics D003879 - Dermatologic Agents > D000982 - Antipruritics CONFIDENCE standard compound; INTERNAL_ID 2746 CONFIDENCE standard compound; INTERNAL_ID 8525 D002491 - Central Nervous System Agents Ondansetron (GR 38032; SN 307) is a highly selective 5-HT3 receptor antagonist, with IC50 value of 103 pM. Ondansetron exerts antiemetic effects by antagonizing 5-HT receptor located on local neurons in the peripheral and central nervous system. Ondansetron suppresses nausea and vomiting caused by chemotherapy and radiation therapy. Ondansetron has orally bioactivity[1][2][3][4][5][6][7][8].
N-Acetylmuramate
This compound belongs to the family of N-acyl-alpha-hexosamines. These are carbohydrate derivatives containing a hexose moeity in which the oxygen atom is replaced by an n-acyl group. KEIO_ID A191
4-(8-Methyl-9H-1,3-dioxolo(4,5-h)(2,3)benzodiazepin-5-yl)benzenamine
D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D002491 - Central Nervous System Agents > D000927 - Anticonvulsants D020011 - Protective Agents
S-(Indolylmethylthiohydroximoyl)-L-cysteine
Dehydronuciferine
Dehydronuciferine is found in coffee and coffee products. Dehydronuciferine is an alkaloid from the leaves of Nelumbo nucifera (East Indian lotus). Dehydronuciferine is an isoquinoline alkaloid. Dehydronuciferine is a natural product found in Nelumbo nucifera with data available. Dehydronuciferine is isolated from the leaves of Nelumbo nucifera Gaertn, a acetylcholinesterase (AChE) inhibitor with an IC50 of 25 μg/mL[1]. Dehydronuciferine is isolated from the leaves of Nelumbo nucifera Gaertn, a acetylcholinesterase (AChE) inhibitor with an IC50 of 25 μg/mL[1].
N-Fructosyl isoleucine
Fructose aminoacids are naturally occurring compounds derived from D-fructose and L-aminoacids. They are amadori products resulting from sugar-aminoacid interactions in food products, especially cooked foods [CCD] N-(1-Deoxy-1-fructosyl)isoleucine is classified as a Natural Food Constituent (code WA) in the DFC.
(3R)-3,4-Dihydroxy-3-(hydroxymethyl)butanenitrile 4-glucoside
(3R)-3,4-Dihydroxy-3-(hydroxymethyl)butanenitrile 4-glucoside is found in cereals and cereal products. (3R)-3,4-Dihydroxy-3-(hydroxymethyl)butanenitrile 4-glucoside is a constituent of barley (Hordeum vulgare). Constituent of barley (Hordeum vulgare). (3R)-3,4-Dihydroxy-3-(hydroxymethyl)butanenitrile 4-glucoside is found in barley and cereals and cereal products.
Koenimbine
Koenimbine is found in herbs and spices. Koenimbine is an alkaloid from leaves and fruits of Murraya koenigii (curryleaf tree
Phenylalanylglutamine
Phenylalanylglutamine is a dipeptide composed of phenylalanine and glutamine. It is an incomplete breakdown product of protein digestion or protein catabolism. Dipeptides are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. Some dipeptides are known to have physiological or cell-signalling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.
Glutaminylphenylalanine
Glutaminylphenylalanine is a dipeptide composed of glutamine and phenylalanine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.
Phenylalanyl-Gamma-glutamate
Phenylalanyl-Gamma-glutamate is a dipeptide composed of phenylalanine and gamma-glutamate. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.
Galactosyl 4-hydroxyproline
Galactosyl 4-hydroxyproline is found in cereals and cereal products. Galactosyl 4-hydroxyproline is isolated from hydrolyzed wheat endosperm. Isolated from hydrolysed wheat endosperm. Galactosyl 4-hydroxyproline is found in cereals and cereal products.
4-Hydroxyproline galactoside
4-Hydroxyproline galactoside is found in cereals and cereal products. 4-Hydroxyproline galactoside is isolated from hydrolyzed wheat endosperm. Isolated from hydrolysed wheat endosperm. 4-Hydroxyproline galactoside is found in cereals and cereal products.
N-(1-Deoxy-1-fructosyl)leucine
Fructose aminoacids are naturally occurring compounds derived from D-fructose and L-aminoacids. They are amadori products resulting from sugar-aminoacid interactions in food products, especially cooked foods [CCD] N-(1-Deoxy-1-fructosyl)leucine is classified as a Natural Food Constituent (code WA) in the DFC.
Pimethixene
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist Pimethixene is a thioxanthene H1-antihistamine.
3,4,5-Trihydroxypentanoylcarnitine
3,4,5-trihydroxypentanoylcarnitine is an acylcarnitine. More specifically, it is an 3,4,5-trihydroxypentanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,4,5-trihydroxypentanoylcarnitine is therefore classified as a short chain AC. As a short-chain acylcarnitine 3,4,5-trihydroxypentanoylcarnitine is a member of the most abundant group of carnitines in the body, comprising more than 50\\% of all acylcarnitines quantified in tissues and biofluids (PMID: 31920980). Some short-chain carnitines have been studied as supplements or treatments for a number of diseases, including neurological disorders and inborn errors of metabolism. Carnitine acetyltransferase (CrAT, EC:2.3.1.7) is responsible for the synthesis of all short-chain and short branched-chain acylcarnitines (PMID: 23485643). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Acridine carboxamide
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D004791 - Enzyme Inhibitors
Islatravir
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D018894 - Reverse Transcriptase Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors
N-(2-Guanidinoethyl)-5-isoquinolinesulfonamide
D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators
N'-[(4-Oxo-4H-chromen-3-yl)methylene]nicotinohydrazide
Dehydronuciferine
Dehydronuciferine is isolated from the leaves of Nelumbo nucifera Gaertn, a acetylcholinesterase (AChE) inhibitor with an IC50 of 25 μg/mL[1]. Dehydronuciferine is isolated from the leaves of Nelumbo nucifera Gaertn, a acetylcholinesterase (AChE) inhibitor with an IC50 of 25 μg/mL[1].
2-Imino-1-isobutyl-5-oxo-1,5-dihydro-2H-dipyrido[1,2-a:2,3-d]pyrimidine-3-carbonitrile
1-(4-Methoxybenzyl)-6,7-methylenedioxyisoquinoline
6-hydroxy-3,3-dimethyl-12H-pyrano[2,3-c]acridin-7-one
8-methoxy-3,3,9-trimethyl-3,11-dihydro-pyrano[3,2-a]carbazole|Koenimbin
2-acetamido-4-O-((S)-1-carboxyethyl)-2-deoxy-D-glucopyranose|2-acetamido-4-O-<(S)-1-carboxyethyl>-2-deoxy-D-glucopyranose
5-methoxy-3,3,8-trimethyl-3,11-dihydro-pyrano[3,2-a]carbazole|Heptazolidine
(1S,2S,5R,7R,9S,E)-5-(5-hydroxy-9-methyl-3-oxo-4-oxatricyclo[3.3.1.02,7]non-2-yl)-2-methyl-4-oxopent-2-enamide|Brasilamide A
5-acetyl-3-deoxyadenosine|5-O-acetyl-3-deoxyadenosine|9-(5-O-acetyl-3-deoxy-beta-D-erythro-pentofuranosyl)adenine
(8aR,9R,11R,12aR)-3-chloro-6,7,8,8a,9,10,11,12-octahydro-14-hydroxy-11-methyl-4H-9,1-ethanylylidenebenzo[i]quinolizin-13-one|2-chlorohuperzine E
N-[2-(1H-indol-3-yl)ethyl]-2-(methylamino)benzamide
4-{(2E)-2-[dihydro-5-methyl-2-oxo-5-(2-oxopropyl)furan-3(2H)-ylidene]ethyl}piperidine-2,6-dione|dipteronine A
Indolo[3,2,1-ij]quinolino[4,5-bc][1,5]naphthyridine
Paclobutrazol
CONFIDENCE standard compound; EAWAG_UCHEM_ID 3705
oxaprozin
M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AE - Propionic acid derivatives D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics C471 - Enzyme Inhibitor > C1323 - Cyclooxygenase Inhibitor D000893 - Anti-Inflammatory Agents D004791 - Enzyme Inhibitors Oxaprozin is an orally active and potent COX inhibitor, with IC50 values of 2.2 μM for human platelet COX-1 and and 36 μM for IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB. Oxaprozin induces cell apoptosis. Oxaprozin shows anti-inflammatory activity. Oxaprozin-mediated inhibition of the Akt/IKK/NF-κB pathway contributes to its anti-inflammatory properties[1][2].
C14H19N3O4_N~5~-Carbamoyl-N~2~-(phenylacetyl)ornithine
ondansetron
A - Alimentary tract and metabolism > A04 - Antiemetics and antinauseants > A04A - Antiemetics and antinauseants > A04AA - Serotonin (5ht3) antagonists C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist > C94726 - 5-HT3 Receptor Antagonist D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics D003879 - Dermatologic Agents > D000982 - Antipruritics D002491 - Central Nervous System Agents Ondansetron (GR 38032; SN 307) is a highly selective 5-HT3 receptor antagonist, with IC50 value of 103 pM. Ondansetron exerts antiemetic effects by antagonizing 5-HT receptor located on local neurons in the peripheral and central nervous system. Ondansetron suppresses nausea and vomiting caused by chemotherapy and radiation therapy. Ondansetron has orally bioactivity[1][2][3][4][5][6][7][8].
O-DeMethylfoliosidine
SubCategory_DNP: : Alkaloids derived from anthranilic acid, Quinoline alkaloids, Foliosidine alkaloids
Fabesetron
C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist > C94726 - 5-HT3 Receptor Antagonist CONFIDENCE standard compound; INTERNAL_ID 393; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3660; ORIGINAL_PRECURSOR_SCAN_NO 3659 CONFIDENCE standard compound; INTERNAL_ID 393; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3638; ORIGINAL_PRECURSOR_SCAN_NO 3636 CONFIDENCE standard compound; INTERNAL_ID 393; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3651; ORIGINAL_PRECURSOR_SCAN_NO 3649 CONFIDENCE standard compound; INTERNAL_ID 393; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3679; ORIGINAL_PRECURSOR_SCAN_NO 3675 CONFIDENCE standard compound; INTERNAL_ID 393; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3688; ORIGINAL_PRECURSOR_SCAN_NO 3687 DATASET 20200303_ENTACT_RP_MIX505; CONFIDENCE standard compound; INTERNAL_ID 393; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3974; ORIGINAL_PRECURSOR_SCAN_NO 3970 CONFIDENCE standard compound; INTERNAL_ID 393; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3974; ORIGINAL_PRECURSOR_SCAN_NO 3970 CONFIDENCE standard compound; INTERNAL_ID 393; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8035; ORIGINAL_PRECURSOR_SCAN_NO 8033 INTERNAL_ID 393; CONFIDENCE standard compound; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8035; ORIGINAL_PRECURSOR_SCAN_NO 8033 CONFIDENCE standard compound; INTERNAL_ID 393; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8049; ORIGINAL_PRECURSOR_SCAN_NO 8045 CONFIDENCE standard compound; INTERNAL_ID 393; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8030; ORIGINAL_PRECURSOR_SCAN_NO 8029 CONFIDENCE standard compound; INTERNAL_ID 393; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8041; ORIGINAL_PRECURSOR_SCAN_NO 8036 CONFIDENCE standard compound; INTERNAL_ID 393; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8063; ORIGINAL_PRECURSOR_SCAN_NO 8062 CONFIDENCE standard compound; INTERNAL_ID 393; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7948; ORIGINAL_PRECURSOR_SCAN_NO 7944
Naphthol AS-OL
CONFIDENCE standard compound; INTERNAL_ID 649; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5054; ORIGINAL_PRECURSOR_SCAN_NO 5049 CONFIDENCE standard compound; INTERNAL_ID 649; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5079; ORIGINAL_PRECURSOR_SCAN_NO 5074 CONFIDENCE standard compound; INTERNAL_ID 649; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5032; ORIGINAL_PRECURSOR_SCAN_NO 5030 CONFIDENCE standard compound; INTERNAL_ID 649; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5075; ORIGINAL_PRECURSOR_SCAN_NO 5073 CONFIDENCE standard compound; INTERNAL_ID 649; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5061; ORIGINAL_PRECURSOR_SCAN_NO 5057 CONFIDENCE standard compound; INTERNAL_ID 649; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5055; ORIGINAL_PRECURSOR_SCAN_NO 5054 CONFIDENCE standard compound; INTERNAL_ID 649; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9521; ORIGINAL_PRECURSOR_SCAN_NO 9519 CONFIDENCE standard compound; INTERNAL_ID 649; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9583; ORIGINAL_PRECURSOR_SCAN_NO 9581 CONFIDENCE standard compound; INTERNAL_ID 649; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9626; ORIGINAL_PRECURSOR_SCAN_NO 9624 CONFIDENCE standard compound; INTERNAL_ID 649; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9630; ORIGINAL_PRECURSOR_SCAN_NO 9625 CONFIDENCE standard compound; INTERNAL_ID 649; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9646; ORIGINAL_PRECURSOR_SCAN_NO 9645
TRIADIMEFON
D016573 - Agrochemicals D010575 - Pesticides
1,2,3,4-Tetrahydro-2-[(isopropylamino)methyl]-7-nitro-6-quinolinecarboxylic acid
Pimethixene
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist
Galactosyl 4-hydroxyproline
4-Hydroxyproline galactoside
(3R)-3,4-Dihydroxy-3-(hydroxymethyl)butanenitrile 4-glucoside
METHYL 1-(4-(2-OXOACETYL)PHENYL)PIPERIDINE-4-CARBOXYLATE HYDRATE
2-(2-AMINOPHENYL)-5-(4-(TERT-BUTYL)PHENYL)-1,3,4-OXADIAZOLE
3-(2-CARBOXY-ETHYL)-MORPHOLINE-4-CARBOXYLIC ACID BENZYL ESTER
Benserazide hydrochloride
C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent C471 - Enzyme Inhibitor
2-(1,3-benzoxazol-2-yl)-1-(4-tert-butylphenyl)ethanone
N-Benzyl-1-(2,4-dimethoxyphenyl)methanamine hydrochloride
3,5-Dip-tolyl-4,5-dihydro-1H-pyrazole-1-carboxamide
Benzoic acid, 4-[(3-formyl-1H-indol-1-yl)methyl]-, methyl ester (9CI)
Benzoic acid, 4-[(3-formyl-2-methyl-1H-indol-1-yl)methyl]- (9CI)
1-(3,4-DIHYDRO-2H-1,5-BENZODIOXEPIN-7-YL)ETHAN-1-ONE
(1-Furan-2-yl-2-phenyl-ethyl)-(4-methoxy-phenyl)-amine
2-[(Tert-Butyloxycarbonyl)]-6-Hydroxy-1,2,3,4-Tetrahydroisoquinoline-3-Carboxylic Acid
(2S,5R)-5-Hydroxy-1,2-piperidinedicarboxylic acid 2-methyl 1-benzyl ester
2-(3-Methoxyphenyl)-6-methylquinoline-4-carboxylic acid
2-(2-Methoxyphenyl)-8-methylquinoline-4-carboxylic acid
2-(3-Methoxyphenyl)-8-methylquinoline-4-carboxylic acid
2-(4-Methoxyphenyl)-8-methylquinoline-4-carboxylic acid
1-(4-nitrophenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
dimazole
D - Dermatologicals > D01 - Antifungals for dermatological use > D01A - Antifungals for topical use C254 - Anti-Infective Agent > C514 - Antifungal Agent
2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)ANILINE DIHYDROCHLORIDE
4-(3-(Trifluoromethyl)benzoyl)-piperidine hydrochloride
ethyl 4-(4-fluorophenyl)-1-methyl-2,6-dioxopiperidine-3-carboxylate
METHYL 5-(TERT-BUTYL)-1-(6-CHLOROPYRIDIN-2-YL)-1H-PYRAZOLE-4-CARBOXYLATE
N-(2-OXO-5-PHENYL-2,3-DIHYDRO-1H-BENZO[E][1,4]DIAZEPIN-3-YL)-ACETAMIDE
3-Carboxy-5-nitrobenzeneboronic acid pinacol ester
azane,2-ethyl-2-(hydroxymethyl)propane-1,3-diol,furan-2,5-dione,oxirane
2-amino-6-(4-phenylmethoxyphenyl)-1H-pyrimidin-4-one
(S)-METHYL3-(4-HYDROXY-3-NITROPHENYL)-2-(2,2,2-TRIFLUOROACETYLAMINO)PROPIONATE
Spiro[2H-1-benzopyran-2,2-[2H]indol]-6-ol,1,3-dihydro-1,3,3-trimethyl-
N-(3-oxo-1-phenyl-2H-pyrazol-4-yl)-2-phenyl-acetamide
(2-((tert-Butyldimethylsilyloxy)methyl)furo[3,2-b]pyridin-6-yl)methanol
1-(5-(TERT-BUTYL)ISOXAZOL-3-YL)-3-(4-CHLOROPHENYL)UREA
1-(5-(TERT-BUTYL)ISOXAZOL-3-YL)-3-(3-CHLOROPHENYL)UREA
3-(4-NITRO-PHENYL)-1-PHENYL-1H-PYRAZOLE-4-CARBALDEHYDE
tert-butyl-dimethyl-(1-methylsulfonylpiperidin-4-yl)oxysilane
6-chloro-2-(2-cyclopentylethyl)imidazo[1,2-b]pyridazine-3-carboxylic acid
1-cbz-4(r)-hydroxypyrrolidine-2-carboxylic acid ethyl ester
N-(2-(2-Methoxyphenoxy)ethyl)benzylamine hydrochloride
1-(BETA-D-2-DEOXYRIBOFURANOSYL)-4-(1,2,4-TRIAZOL-1-YL)-5-METHYLPYRIMIDIN-2-ONE
DIETHYL 2-(((2-METHOXYPHENYL)AMINO)METHYLENE)MALONATE
4-(tert-butoxycarbonyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-7-carboxylic acid
(2R,5R)-5-Hydroxy-1,2-piperidinedicarboxylic acid 2-methyl 1-benzyl ester
(2R-trans)-5-Hydroxy-1,2-piperidinedicarboxylic acid 2-methyl 1-benzyl ester
(2S,5S)-5-Hydroxy-1,2-piperidinedicarboxylic acid 2-methyl 1-benzyl ester
(4-{[(2-Methyl-2-propanyl)oxy]carbonyl}-2,3,4,5-tetrahydro-1,4-be nzoxazepin-7-yl)boronic acid
3-(4-FLUORO-PHENYLCARBAMOYL)-1,2,2-TRIMETHYL-CYCLOPENTANECARBOXYLIC ACID
2-Boc-6-Hydroxy-1,2,3,4-tetrahydro-isoquinoline-1-carboxylic acid
2-(3-METHOXYPHENYL)PYRIDO[3,2:4,5]FURO[3,2-D]PYRIMIDIN-4(3H)-ONE
Methoxypolyethylene glycol 5,000 acetic acid N-succinimidyl ester
4-Quinolinecarboxylic acid, 2-(4-Methoxyphenyl)-, Methyl ester
Methyl 2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate
1H-Indole-1-acetamide,3-formyl-2-methyl-N-2-pyridinyl-(9CI)
Piperidin-4-yl (2-(trifluoromethyl)phenyl)methanone hydrochloride
(S)-3-BENZYLOXYCARBONYL-5-OXO-4-OXAZOLIDINEPROPANOIC ACID
TRANS-1-BENZYL 2-ETHYL 4-HYDROXYPYRROLIDINE-1,2-DICARBOXYLATE
1H-INDOL-3-YL[3-(4-METHOXYPHENYL)OXIRAN-2-YL]METHANONE
tert-butyl N-(1,3-benzodioxol-5-ylmethyl)-N-(2-oxoethyl)carbamate
2-Cyclopropyl-4-(4-fluorophenyl)-quinolyl-3-methanol
trans-3-Ethoxycarbonyl-4-(4-flurophenyl)-N-methyl piperdine-2,6-dione
1-[2-(3,5-dimethylphenoxy)ethyl]indole-3-carbaldehyde
2-amino-3-nitro-4-phenyl-5,6,7,8-tetrahydronaphthalene-1-carbonitrile
(3R)-2-(tert-Butoxycarbonyl)-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
2-[(3-METHOXYPHENYLAMINO)-METHYLENE]MALONIC ACID DIETHYL ESTER
(S)-3-BENZYL 4-METHYL 2,2-DIMETHYLOXAZOLIDINE-3,4-DICARBOXYLATE
Methyl (3R)-(-)-3-(methyl-1H-Indol-3-yl)-3-phenylpropanoate
Methyl 7-isobutyl-1,3-diMethyl-2,4-dioxo-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-d]pyriMidine-6-carboxylate
TERT-BUTYL 3-(((METHYLSULFONYL)OXY)METHYL)PIPERIDINE-1-CARBOXYLATE
tert-Butyl 4-(((methylsulfonyl)oxy)methyl)piperidine-1-carboxylate
2-amino-9-((3aS,4S,6S,6aR)-3a,6-dihydroxyhexahydro-1H-cyclopenta[c]furan-4-yl)-1,9-dihydro-6H-purin-6-one
MK-8591
C471 - Enzyme Inhibitor > C1589 - Reverse Transcriptase Inhibitor > C97452 - Nucleoside Reverse Transcriptase Inhibitor D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D018894 - Reverse Transcriptase Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors C254 - Anti-Infective Agent > C281 - Antiviral Agent
(R)-tert-Butyl 2-(dimethylcarbamoyl)piperazine-1-carboxylate hydrochloride
ethyl 1-cyclopropyl-6,7-difluoro-4-oxoquinoline-3-carboxylate
(2S)-2-acetamido-4-methyl-N-(4-nitrophenyl)pentanamide
ethyl 2-(4-amino-3-methoxyphenyl)-3,3,3-trifluoro-2-hydroxypropanoate
Benzeneethanamine,3-methoxy-4-(phenylmethoxy)-, hydrochloride (1:1)
Methyl 2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate
3-NITRO-4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZOIC ACID
2-(4-Ethoxy-3-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
(1-(TERT-BUTYLDIMETHYLSILYL)-5-FLUORO-1H-INDOL-4-YL)BORONIC ACID
(3R,4S)-1-[(4-Amino-5H-pyrrolo[3,2-D]pyrimidin-7-YL)methyl]-4-[(methylsulfanyl)methyl]pyrrolidin-3-OL
5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine
3-(4-Fluorophenyl)-2-(6-methylpyridin-2-YL)-5,6-dihydro-4H-pyrrolo[1,2-B]pyrazole
(1S)-1-(4-chlorophenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-one
(R)-6-Allyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
N-(4-ethylphenyl)-4-oxo-3H-phthalazine-1-carboxamide
3-[(6-Methyl-4-phenyl-2-quinazolinyl)amino]-1-propanol
3-(4-Azidobenzyl)-4-hydroxycoumarin
D006401 - Hematologic Agents > D000925 - Anticoagulants > D015110 - 4-Hydroxycoumarins
(4-Benzoyl-1-methyl-3-pyrrolidinyl)-phenylmethanone
7-Methyl-4-oxo-2-[(phenylmethyl)amino]-3-pyrido[1,2-a]pyrimidinecarboxaldehyde
9-Amino-5-(2-aminopyrimidin-4-yl)pyrido[3,2:4,5]pyrrolo[1,2-c]pyrimidin-4-ol
3-{[(1R)-1-phenylethyl]amino}-4-(pyridin-4-ylamino)cyclobut-3-ene-1,2-dione
4-(4-Fluorophenyl)-1-cycloropropylmethyl-5-(4-pyridyl)-imidazole
2,6-Diamino-8-(2-dimethylaminoethylsulfanylmethyl)-3H-quinazolin-4-one
4-[5-(7-Aza-bicyclo[2.2.1]hept-2-yl)-2-fluoro-pyridin-3-yl]-benzonitrile
N,N-Dimethyl-N-(acetyl)-N-(7-nitrobenz-2-oxa-1,3-diazol-4-YL)ethylenediamine
3-Methyl-2-[[2,3,4-trihydroxy-5-(hydroxymethyl)oxolan-2-yl]methylamino]pentanoic acid
5,10-Dihydro-9-dimethylallylphenazine 1-carboxylate
A monocarboxylic acid anion that is the conjugate base of 5,10-9-dimethylallyldihydrophenazine-1-carboxylic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
1-(4-Chlorophenoxy)-3,3-dimethyl-1-(triazol-2-yl)butan-2-one
(2R)-2-amino-3-[(E)-N-hydroxy-C-(1H-indol-3-ylmethyl)carbonimidoyl]sulfanylpropanoic acid
(E)-1-(L-cystein-S-yl)-N-hydroxy-2-(1H-indol-3-yl)ethan-1-imine
N,N,4-trimethyl-2-[[(5-methyl-2-furanyl)-oxomethyl]amino]-5-thiazolecarboxamide
3-[5-Amino-3-(4-chlorophenyl)-1-pyrazolyl]propanoic acid ethyl ester
4-(2-Furanyl)-3-methyl-5-(4-methylphenyl)-2,4-dihydropyrrolo[3,4-c]pyrazol-6-one
N-(4-hydroxyphenyl)-3-methoxy-2-naphthalenecarboxamide
N-(4-cyclohexylphenyl)-2-(2-hydroxyethylthio)acetamide
(2R)-2-amino-3-[(Z)-N-hydroxy-C-(1H-indol-3-ylmethyl)carbonimidoyl]sulfanylpropanoic acid
5-(Carbamoylamino)-2-[(2-phenylacetyl)amino]pentanoic acid
N-[(E)-(4-Fluorophenyl)methylideneamino]-2,6-dimethylquinolin-4-amine
Phe-Ala-Gly
A tripeptide composed of L-phenylalanine, L-alanine, and glycine joined by peptide linkages.
2-Butanone, 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1H-1,2,4-triazol-1-yl)-, (1R)-
2-ethoxy-N-[5-(methoxymethyl)-1,3,4-thiadiazol-2-yl]benzamide
3-[(2-Hydroxyphenyl)hydrazinylidene]-1-prop-2-enyl-2-indolone
4-methyl-N-[(1-oxopentylhydrazo)-sulfanylidenemethyl]benzamide
3-hydroxy-7-methyl-3-(4-morpholinyl)-5-nitro-1H-indol-2-one
5-(4-methylphenyl)-N-(3-pyridinylmethyl)-3-isoxazolecarboxamide
2-(2,3-dihydro-1H-inden-5-yloxy)-1-(2,3-dihydroindol-1-yl)ethanone
4-methylbenzoic acid [2-(1H-indol-3-yl)-2-oxoethyl] ester
3-[1-(3-Methoxypropyl)-5-thiophen-2-yl-2-pyrrolyl]propanoic acid
4-(6-Quinolinyl)-1,3,4,6,7,8-hexahydroquinazoline-2,5-dione
1-[2-(4-Morpholinyl)-2-oxoethyl]-2-pyrido[2,3-b][1,4]thiazinone
3-(1H-indazol-6-yl)-1-propan-2-yl-4-pyrazolo[3,4-d]pyrimidinamine
4-[[(2,3-Dihydro-2,2-dimethyl-7-benzofuranyloxy)carbonyl]-amino]butanoic acid
9-Ethyl-6-[2-(3-pyridinyl)ethylamino]-2-purinecarbonitrile
2-[[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)-4-oxanyl]oxy]propanoic acid
2-[(1S,3S,4aS,9aR)-6-amino-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
methyl 2-[(1S,3S,4aR,9aS)-6-amino-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]acetate
methyl 2-[(1R,3S,4aR,9aS)-6-amino-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]acetate
2-[(1S,3R,4aS,9aR)-6-amino-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
2-[(1R,3S,4aS,9aR)-6-amino-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
2-[(1S,3R,4aR,9aS)-6-amino-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
2-[(1R,3R,4aS,9aR)-6-amino-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
methyl 4,6-dideoxy-4-[(2S)-2,4-dihydroxybutanamido]-2-O-methyl-alpha-D-mannopyranoside
4-[3,4,5-Trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypyrrolidine-2-carboxylic acid
1-S-(N-hydroxypent-4-enimidoyl)-1-thio-beta-D-glucopyranose
(2S)-2-azaniumyl-5-{[(1S)-1-carboxylato-2-phenylethyl]amino}-5-oxopentanoate
6-Methyl-3-[2-(4-methylphenyl)-2-oxoethyl]-1,4-benzoxazin-2-one
4-Acetyl-5-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidine-2,3-dione
2-amino-5-(aminomethyl)-7-[4-hydroxy-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-3H-pyrrolo[2,3-d]pyrimidin-4-one
trans-2-Hexenal oxime, o-[(pentafluorophenyl)methyl]-
GYKI 52466
D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D002491 - Central Nervous System Agents > D000927 - Anticonvulsants D020011 - Protective Agents
N-(2-Guanidinoethyl)-5-isoquinolinesulfonamide
D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators
Phenanthro(3,4-d)-1,3-dioxole-5-ethanamine, N,N-dimethyl-
2-[3-Acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoic acid
3-butenyldesulfoglucosinolate
A desulfoglucosinolic acid resulting from the formal condensation of the thiol group of N-hydroxypent-4-enethioamide with beta-D-glucopyranose.
gamma-Glu-Phe(1-)
A peptide anion obtained by deprotonation of both carboxy groups and protonation of the glutamyl amino group of gamma-Glu-Phe. Major species at pH 7.3.
(8R)-7-prop-2-enyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-13,14-diol
(+)-N-Allylnormetazocine (hydrochloride)
(+)-N-Allylnormetazocine ((+)-SKF 10047) hydrochloride is a benzomorphan opioid with psychotomi metic effects. (+)-N-Allylnormetazocine hydrochloride is an opioid receptor antagonist with Ki values of 300 nM and 27 μM for σ1 and σ2 opioid receptors, respectively. (+)-N-Allylnormetazocine hydrochloride can be used for the research of neurological disease[1][2].
CP94253 (hydrochloride)
CP94253 hydrochloride is a potent and selective agonist of 5-HT1B receptor (Ki= 2 nM in a radioligand binding assay).Ki values for 5-HT1A, 5-HT1D, 5-HT1C and 5-HT2 receptors are 89, 49, 860, and 1600 nM respectively[1]. CP94253 hydrochloride is centrally active upon systemic administration in vivo[2].
